The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma

(2015) Lawrence N. Kwong et al.   JOURNAL OF CLINICAL INVESTIGATION

Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis

(2015) M. Fallahi-Sichani et al.   Molecular Systems Biology

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Editorial: Cellular and Phenotypic Plasticity in Cancer

(2015) Petranel T. Ferrao et al.   Frontiers in Oncology

Phenotype Switching in Melanoma: Implications for Progression and Therapy

(2015) Frederic Zhentao Li et al.   Frontiers in Oncology

Plasticity of melanoma and EMT-TF reprogramming

(2015) Eugene Tulchinsky et al.   Oncotarget

Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma

(2015) Aparna Jayachandran et al.   Oncotarget

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy

(2014) K. Kemper et al.   CANCER RESEARCH

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

(2014) Jamie N. Anastas et al.   JOURNAL OF CLINICAL INVESTIGATION

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma

(2014) M. A. Smit et al.   Molecular Systems Biology

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

(2014) Richard J. Young et al.   Pigment Cell & Melanoma Research

Adaptive resistance to RAF inhibitors in melanoma

(2014) Curtis H. Kugel et al.   Pigment Cell & Melanoma Research

Signaling mechanisms of the epithelial-mesenchymal transition

(2014) D. M. Gonzalez et al.   Science Signaling

Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

(2014) T. J. Parmenter et al.   Cancer Discovery

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

JNK signalling in cancer: in need of new, smarter therapeutic targets

(2013) Concetta Bubici et al.   BRITISH JOURNAL OF PHARMACOLOGY

A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma

(2013) Julie Caramel et al.   CANCER CELL

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

AP-1/c-Jun transcription factors: Regulation and function in malignant melanoma

(2013) Melanie Kappelmann et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression

(2013) Georgina V. Long et al.   Pigment Cell & Melanoma Research

The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel

(2013) Andreas Behren et al.   Pigment Cell & Melanoma Research

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

(2013) M. P. O'Connell et al.   Cancer Discovery

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma

(2012) S Hagiwara et al.   BRITISH JOURNAL OF CANCER

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

(2012) Piro Lito et al.   CANCER CELL

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

(2011) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma

(2011) Barbara Spangler et al.   INTERNATIONAL JOURNAL OF CANCER

Requirement of c-Jun NH2-Terminal Kinase for Ras-Initiated Tumor Formation

(2011) C. Cellurale et al.   MOLECULAR AND CELLULAR BIOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

(2011) P T Ferrao et al.   ONCOGENE

Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching

(2011) Ossia M. Eichhoff et al.   Pigment Cell & Melanoma Research

Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome

(2010) G. Jonsson et al.   CLINICAL CANCER RESEARCH

The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report

(2010) Ossia M. Eichhoff et al.   MELANOMA RESEARCH

Evaluation of molecular markers of mesenchymal phenotype in melanoma

(2010) Leann M. Mikesh et al.   MELANOMA RESEARCH

Sustained c-Jun-NH2-Kinase Activity Promotes Epithelial-Mesenchymal Transition, Invasion, and Survival of Breast Cancer Cells by Regulating Extracellular Signal-Regulated Kinase Activation

(2010) J. Wang et al.   MOLECULAR CANCER RESEARCH

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Cancer stem cells versus phenotype-switching in melanoma

(2010) Keith S. Hoek et al.   Pigment Cell & Melanoma Research

Post-transcriptional regulation controlled by E-cadherin is important for c-Jun activity in melanoma

(2010) B. Spangler et al.   Pigment Cell & Melanoma Research

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

Loss of E-Cadherin–mediated Cell–Cell Contacts Activates a Novel Mechanism for Up-Regulation of the Proto-Oncogene c-Jun

(2009) Revital Knirsh et al.   MOLECULAR BIOLOGY OF THE CELL

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH

Receptor Tyrosine Kinase Ror2 Mediates Wnt5a-induced Polarized Cell Migration by Activating c-Jun N-terminal Kinase via Actin-binding Protein Filamin A

(2008) Akira Nomachi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY